Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

被引：109

作者：

Wolf, Jeffrey L. ^{[2
]}

Siegel, David ^{[3
]}

Goldschmidt, Hartmut ^{[4
]}

Hazell, Katharine ^{[5
]}

Bourquelot, Priscille M. ^{[5
]}

Bengoudifa, Bourras R. ^{[5
]}

Matous, Jeffrey ^{[6
]}

Vij, Ravi ^{[7
]}

de Magalhaes-Silverman, Margarida ^{[8
]}

Abonour, Rafat ^{[9
]}

Anderson, Kenneth C. ^{[10
]}

Lonial, Sagar ^{[1
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[4] Heidelberg Univ, Heidelberg, Germany

[5] Novartis Pharma AG, Basel, Switzerland

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Washington Univ, St Louis, MO USA

[8] Univ Iowa, Iowa City, IA USA

[9] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA

[10] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 09期

关键词：

BORTEZOMIB; LBH589; PROTEASOME; SURVIVAL;

D O I：

10.3109/10428194.2012.661175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1820 / 1823

页数：4

共 15 条

[1] Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges [J].

Atadja, Peter .

CANCER LETTERS, 2009, 280 (02) :233-241

[2] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].

Bali, P ;

Pranpat, M ;

Bradner, J ;

Balasis, M ;

Fiskus, W ;

Guo, F ;

Rocha, K ;

Kumaraswamy, S ;

Boyapalle, S ;

Atadja, P ;

Seto, E ;

Bhalla, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734

[3] Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells [J].

Catley, Laurence ;

Weisberg, Ellen ;

Kiziltepe, Tanyel ;

Tai, Yu-Tzu ;

Hideshima, Teru ;

Neri, Paola ;

Tassone, Pierfrancesco ;

Atadja, Peter ;

Chauhan, Dharminder ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. .

BLOOD, 2006, 108 (10) :3441-3449

[4] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[5] Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma [J].

Ellis, Leigh ;

Pan, Yan ;

Smyth, Gordon K. ;

George, Daniel J. ;

McCormack, Chris ;

Williams-Truax, Roxanne ;

Mita, Monica ;

Beck, Joachim ;

Burris, Howard ;

Ryan, Gail ;

Atadja, Peter ;

Butterfoss, Dale ;

Dugan, Margaret ;

Culver, Kenneth ;

Johnstone, Ricky W. ;

Prince, H. Miles .

CLINICAL CANCER RESEARCH, 2008, 14 (14) :4500-4510

[6] Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma [J].

Hideshima, T ;

Bradner, JE ;

Wong, J ;

Chauhan, D ;

Richardson, P ;

Schreiber, SL ;

Anderson, KC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (24) :8567-8572

[7] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].

Kumar, S. K. ;

Lee, J. H. ;

Lahuerta, J. J. ;

Morgan, G. ;

Richardson, P. G. ;

Crowley, J. ;

Haessler, J. ;

Feather, J. ;

Hoering, A. ;

Moreau, P. ;

LeLeu, X. ;

Hulin, C. ;

Klein, S. K. ;

Sonneveld, P. ;

Siegel, D. ;

Blade, J. ;

Goldschmidt, H. ;

Jagannath, S. ;

Miguel, J. S. ;

Orlowski, R. ;

Palumbo, A. ;

Sezer, O. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2012, 26 (01) :149-157

[8] Improved survival in multiple myeloma and the impact of novel therapies [J].

Kumar, Shaji K. ;

Rajkumar, S. Vincent ;

Dispenzieri, Angela ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Zeldenrust, Steven R. ;

Dingli, David ;

Russell, Stephen J. ;

Lust, John A. ;

Greipp, Philip R. ;

Kyle, Robert A. ;

Gertz, Morie A. .

BLOOD, 2008, 111 (05) :2516-2520

[9]

Kyle RA, 2003, BRIT J HAEMATOL, V121, P749

[10] Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma [J].

Niesvizky, Ruben ;

Ely, Scott ;

Mark, Tomer ;

Aggarwal, Sangeeta ;

Gabrilove, Janice L. ;

Wright, John J. ;

Chen-Kiang, Selina ;

Sparano, Joseph A. .

CANCER, 2011, 117 (02) :336-342

← 1 2 →